Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 8:42 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 313–336 of 2,297 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Induction Phase Clear all
Completed Phase 1Phase 2 Interventional

A Phase I/II Study of Induction Chemotherapy With Daunorubicin, Cytarabine, Topotecan and Etoposide

NCT00005793
View directory record Official record
Conditions
Leukemia
Interventions
Cytarabine, Daunorubicin, Etoposide, Topotecan
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
16 Years to 59 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2006
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Sep 25, 2012 · Synced Oct 22, 2026, 8:42 PM EDT
Terminated Not applicable Interventional Results available

Mild Hypothermia and Acute Kidney Injury in Liver Transplantation

NCT03534141
View directory record Official record
Conditions
Cirrhosis, End Stage Liver Disease, Acute Kidney Injury, Liver Transplant; Complications, Chronic Kidney Diseases, Hepatitis c, Hepatitis B, NASH - Nonalcoholic Steatohepatitis, Alcoholic Cirrhosis, Hepatocellular Carcinoma
Interventions
Esophageal cooling/warming device, Mild hypothermia, Normothermia
Device · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
3
States / cities
San Francisco, California • Aurora, Colorado • Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 16, 2025 · Synced Oct 22, 2026, 8:42 PM EDT
Terminated Phase 2 Interventional Results available

Trilaciclib, a CDK 4/6 Inhibitor, in Patients With Advanced/Metastatic Bladder Cancer Receiving Chemotherapy Then Avelumab

NCT04887831
View directory record Official record
Conditions
Urothelial Carcinoma, Bladder Cancer, Myelosuppression Adult, Chemotherapy-induced Neutropenia, Metastatic Bladder Cancer
Interventions
Trilaciclib, Gemcitabine, Cisplatin, Carboplatin, Avelumab
Drug
Lead sponsor
G1 Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
13
States / cities
Los Angeles, California • Whittier, California • Littleton, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2025 · Synced Oct 22, 2026, 8:42 PM EDT
Completed Phase 2 Interventional

Homoharringtonine in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia

NCT00006364
View directory record Official record
Conditions
Childhood Chronic Myelogenous Leukemia, Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Chronic Phase Chronic Myelogenous Leukemia, Relapsing Chronic Myelogenous Leukemia
Interventions
omacetaxine mepesuccinate, pharmacological study, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
12 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 23, 2013 · Synced Oct 22, 2026, 8:42 PM EDT
Completed Phase 1 Interventional

Combination Chemotherapy and Radiation Therapy in Treating Patients Who Are Undergoing Surgery for Locally Advanced Esophageal Cancer

NCT00238147
View directory record Official record
Conditions
Esophageal Cancer
Interventions
capecitabine, carboplatin, docetaxel, conventional surgery, neoadjuvant therapy, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
2
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 17, 2013 · Synced Oct 22, 2026, 8:42 PM EDT
Completed Phase 2 Interventional Results available

Ofatumumab-based Induction Chemoimmunotherapy in Previously Untreated Patients With CLL/SLL

NCT01145209
View directory record Official record
Conditions
Small Lymphocytic Lymphoma, CLL (Chronic Lymphocytic Leukemia)
Interventions
Fludarabine Phosphate, Ofatumumab, Cyclophosphamide
Drug · Biological
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 99 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2023
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 28, 2023 · Synced Oct 22, 2026, 8:42 PM EDT
Terminated Phase 1 Interventional

Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Properties of Oral AT-406 in Combination With Daunorubicin and Cytarabine in Patients With Poor-risk Acute Myelogenous Leukemia (AML)

NCT01265199
View directory record Official record
Conditions
Acute Myelogenous Leukemia (AML)
Interventions
AT-406 in combination with daunorubicin and cytarabine
Drug
Lead sponsor
Ascenta Therapeutics
Industry
Eligibility
18 Years to 74 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
6
States / cities
Chicago, Illinois • Ann Arbor, Michigan • St Louis, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2013 · Synced Oct 22, 2026, 8:42 PM EDT
Completed Phase 2 Interventional

Peripheral Blood Lymphocyte Therapy to Prevent Lymphoproliferative Disorders Caused by Epstein-Barr Virus in Patients Who Have Undergone Transplantation

NCT00005606
View directory record Official record
Conditions
Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
Interventions
allogeneic Epstein-Barr virus-specific cytotoxic T lymphocytes, autologous Epstein-Barr virus-specific cytotoxic T lymphocytes
Biological
Lead sponsor
Northwestern University
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2003
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 6, 2012 · Synced Oct 22, 2026, 8:42 PM EDT
Terminated Phase 2 Interventional Results available

Study of Sotatercept for the Treatment of Chemotherapy Induced Anemia in Patients With Metastatic Breast Cancer (MK-7962-012)

NCT00931606
View directory record Official record
Conditions
Chemotherapy Induced Anemia
Interventions
Sotatercept, Placebo
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
28
States / cities
Sedona, Arizona • Hot Springs, Arkansas • Beverly Hills, California + 25 more
Source: ClinicalTrials.gov public record
Updated Sep 13, 2023 · Synced Oct 22, 2026, 8:42 PM EDT
Withdrawn Phase 2 Interventional

Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Brain Tumor

NCT00003273
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Neuroblastoma, Retinoblastoma, Sarcoma
Interventions
filgrastim, carboplatin, cisplatin, cyclophosphamide, etoposide, leucovorin calcium, methotrexate, temozolomide, thiotepa, vincristine sulfate, autologous bone marrow transplantation, peripheral blood stem cell transplantation, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
NYU Langone Health
Other
Eligibility
Up to 10 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1997
U.S. locations
17
States / cities
Honolulu, Hawaii • Scarborough, Maine • Grand Rapids, Michigan + 11 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2015 · Synced Oct 22, 2026, 8:42 PM EDT
Completed Phase 3 Interventional Results available

Lamotrigine in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer

NCT00068445
View directory record Official record
Conditions
Neurotoxicity, Pain, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
lamotrigine, Placebo
Drug · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2013
U.S. locations
23
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Atlanta, Georgia + 20 more
Source: ClinicalTrials.gov public record
Updated May 4, 2018 · Synced Oct 22, 2026, 8:42 PM EDT
Completed Phase 1 Interventional

Combination Chemotherapy in Treating Young Patients With Relapsed or Refractory Acute Leukemia

NCT00462787
View directory record Official record
Conditions
Leukemia
Interventions
filgrastim, clofarabine, dexamethasone, thiotepa, topotecan hydrochloride, vinorelbine tartrate
Biological · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Up to 28 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 14, 2013 · Synced Oct 22, 2026, 8:42 PM EDT
Suspended Not applicable Interventional Accepts healthy volunteers

Effects of Progesterone on Smoked Nicotine Induced Changes in Hormones and Subjective Ratings of Stimulant Drug Effects

NCT01636336
View directory record Official record
Conditions
Nicotine Dependence
Interventions
Nicotine, Progesterone
Other
Lead sponsor
Mclean Hospital
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2016
U.S. locations
1
States / cities
Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 15, 2013 · Synced Oct 22, 2026, 8:42 PM EDT
Completed Phase 3 Interventional

Cytarabine With or Without VNP40101M in Treating Patients With Relapsed Acute Myeloid Leukemia

NCT00112554
View directory record Official record
Conditions
Leukemia
Interventions
cytarabine, laromustine, placebo
Drug · Other
Lead sponsor
Vion Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
420 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
24
States / cities
Los Angeles, California • Orange, California • San Francisco, California + 19 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2013 · Synced Oct 22, 2026, 8:42 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Lidocaine for Oxaliplatin-induced Neuropathy

NCT03254394
View directory record Official record
Conditions
Neuropathy, Painful, Chemotherapy-induced Peripheral Neuropathy, Colorectal Cancer
Interventions
Lidocaine Hydrochloride, Placebo, FOLFOX regimen
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 9, 2022 · Synced Oct 22, 2026, 8:42 PM EDT
Terminated Phase 2 Interventional Results available

Study of Metformin Plus Paclitaxel/Carboplatin/Bevacizumab in Patients With Adenocarcinoma.

NCT01578551
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung, Lung Adenocarcinoma
Interventions
Paclitaxel, Carboplatin, Bevacizumab, Metformin
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 100 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
2
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 19, 2018 · Synced Oct 22, 2026, 8:42 PM EDT
Completed Phase 3 Interventional Results available

A Study of the Safety and Effectiveness of Apixaban in Preventing Blood Clots in Children With Leukemia Who Have a Central Venous Catheter and Are Treated With Asparaginase

NCT02369653
View directory record Official record
Conditions
Lymphoma, Acute Lymphoblastic Leukemia
Interventions
Apixaban, No systemic anticoagulant prophylaxis
Drug · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
1 Year to 17 Years
Enrollment
512 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
64
States / cities
Phoenix, Arizona • Duarte, California • Loma Linda, California + 56 more
Source: ClinicalTrials.gov public record
Updated Mar 8, 2022 · Synced Oct 22, 2026, 8:42 PM EDT
Completed Phase 3 Interventional Results available

Prevention of Pegfilgrastim-Induced Bone Pain (PIBP)

NCT00602420
View directory record Official record
Conditions
Musculoskeletal Complications, Pain, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
naproxen, placebo
Drug · Other
Lead sponsor
Gary Morrow
Other
Eligibility
18 Years to 120 Years
Enrollment
510 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
16
States / cities
Honolulu, Hawaii • Decatur, Illinois • Evanston, Illinois + 13 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2015 · Synced Oct 22, 2026, 8:42 PM EDT
Completed Not applicable Interventional

Pilot Study to Determine the Feasibility of Fluconazole for Induction Treatment and Suppression of Relapse of Histoplasmosis in Patients With the Acquired Immunodeficiency Syndrome

NCT00000627
View directory record Official record
Conditions
HIV Infections, Histoplasmosis
Interventions
Fluconazole
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1994
U.S. locations
23
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2021 · Synced Oct 22, 2026, 8:42 PM EDT
Completed Phase 2 Interventional Results available

A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Obese Adult Patients With Schizophrenia While Taking Antipsychotic Medications (GRATITUDE II)

NCT04524403
View directory record Official record
Conditions
Antipsychotic-induced Weight Gain (AIWG)
Interventions
Miricorlilant, Placebo
Drug
Lead sponsor
Corcept Therapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
40
States / cities
Bentonville, Arkansas • Little Rock, Arkansas • Culver City, California + 33 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2024 · Synced Oct 22, 2026, 8:42 PM EDT
Terminated Phase 2 Interventional Results available

Romiplostim in Increasing Low Platelet Counts in Patients With Multiple Myeloma Receiving Chemotherapy

NCT01676961
View directory record Official record
Conditions
Refractory Multiple Myeloma, Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma, Thrombocytopenia
Interventions
romiplostim
Biological
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 15, 2018 · Synced Oct 22, 2026, 8:42 PM EDT
Terminated Phase 2Phase 3 Interventional

SPARK-ALL: Calaspargase Pegol in Adults With ALL

NCT04817761
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia
Interventions
Calaspargase pegol (S95015)
Drug
Lead sponsor
Institut de Recherches Internationales Servier
Other
Eligibility
22 Years to 55 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
21
States / cities
Scottsdale, Arizona • Duarte, California • Los Angeles, California + 16 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2026 · Synced Oct 22, 2026, 8:42 PM EDT
Recruiting Phase 2 Interventional

Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL

NCT05082519
View directory record Official record
Conditions
B-cell Acute Lymphoblastic Leukemia, Obesity
Interventions
IDEAL2 Intervention
Behavioral
Lead sponsor
Etan Orgel
Other
Eligibility
7 Years to 25 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2032
U.S. locations
16
States / cities
Los Angeles, California • Orange, California • San Francisco, California + 13 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 22, 2026, 8:42 PM EDT
Completed Phase 3 Interventional Results available

A Phase 3 Study in Participants With Moderate to Severe Psoriasis

NCT01474512
View directory record Official record
Conditions
Psoriasis
Interventions
80 mg Ixekizumab Dosing Regimens 1, 2, and 3, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
1,296 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
34
States / cities
Birmingham, Alabama • Anaheim, California • Bakersfield, California + 31 more
Source: ClinicalTrials.gov public record
Updated Oct 3, 2019 · Synced Oct 22, 2026, 8:42 PM EDT